Navigation Links
Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
Date:6/12/2013

BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany, Italy, Spain and the United Kingdom) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae. Such early-line use of these agents is indicative of the wider prescribing practices that fuel drug resistance and that have led to higher prevalence of carbapenem-resistant Gram-negative pathogens (GNPs), such as KPC-producing Enterobacteriaceae.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Drug-Resistant Gram-Negative Infections: How Will the Threat of Multidrug-Resistant Gram-Negative Pathogens Impact Market Access for Current and Emerging Antibiotics in the EU5? finds that nearly a third of surveyed physicians prescribe combinations of tigecycline (Pfizer's Tygacil), piperacillin/tazobactam (Pfizer's Zosyn/Tazocin; generics), carbapenems, aminoglycosides and polymyxins early in the treatment algorithm for infections due to multi-drug-resistant (MDR) GNPs, like KPC-producing Enterobacteriaceae or MDR-Pseudomonas. Reflective of physician concern over growing prevalence of these MDR pathogens and limited treatment options currently, over three-quarters of those surveyed anticipate prescribing emerging beta-lactam/beta-lactamase inhibitors CAZ-AVI (Forest/AstraZeneca) and CXA-201 (Cubist), primarily as a carbapenem-sparing therapy and as step therapy for patients failing anti-pseudomonal cephalosporin treatment, respectively.

The report also finds that economic hardships in Europe have translated to increasingly constrained hospital budgets. While the most expensive antibiotics are still cheap compared with biologics used in other therapy areas, interviewed payers warn that increasing patient numbers amid tightening budgets may result in insufficient diagnosis-related group reimbursement rates for overall treatment costs of GNIs, thereby forcing careful budget balancing in busy public institutions. Under pressure to optimize hospital and regional formularies by providing a diverse but cost-effective selection of antibiotics, these payers report that evidence of geographically tailored, cost-efficacy benefit is a key market access lever that will allow them to assess the benefits of novel premium-priced antibiotics against the backdrop of a highly genericized market.

"Interviewed Italian payers believe that even though hospitals are under pressure to reduce costs, they are eager for new therapies that effectively target drug-resistant Gram-negative pathogens," said Decision Resources Analyst Maria Ascano, Ph.D. "Novel therapies with such activity have the potential for rapid regional and hospital formulary inclusion; however manufacturers must be prepared for rigorous health technology assessments across the EU5, and must balance pricing expectations against potential uptake in this highly cost-constrained market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
2. Wound Management Products Market Reaches $15.2 Billion by 2016, Driven by Rising Demand for Bandages and Dressings in Developing World
3. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
4. BidOnHealth.com Offers a Solution to Rising Healthcare Costs
5. Independent Schools Consortium Slams Brakes on Rising Health Care Costs
6. Active Pharmaceutical Ingredients (API) Global Market to 2017 - Growth in Developing Markets to Come From Cost Efficient Manufacturing and Rising Domestic Demand
7. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
8. Polymers in Medical Devices: Opportunities Arising and Trends Impacting the Market
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Computer Modeling Reveals How Surprisingly Potent Hepatitis C Drug Works
11. Rising Disease Prevalence Boosts Mexican Healthcare Industry, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink Inc ... for connecting the Life Sciences supply chain and ... today announced that Tjoapack has selected TraceLink,s serialization ... customers comply with the rapidly approaching serialization deadlines ... (DSCSA) in 2017 and the EU Falsified Medicines ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , ... biotechnology company Kadimastem (TASE: KDST) announced today the signing of a ... collaboration between the companies. The synergy between the companies will assist ... collaboration as a worldwide leader in innovative treatment for severe diseases ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):